Changchun High-Tech receives approval for leuprorelin injection

Changchun High & New Technology Industry Group's subsidiary, Changchun Jinsai Pharmaceutical, has received acceptance from the National Medical Products Administration for its marketing application for Leuprorelin injection emulsion, a long-acting GnRH agonist for advanced prostate cancer treatment. This product, developed in partnership with YiDa Biotechnology, offers a six-month dosing interval. The product is already approved in the US, Canada, the EU, and Taiwan. It addresses a growing domestic need, with China's age-standardized incidence rate of prostate cancer (ASIR) projected to rise from 18.72/100,000 in 2019 to 25.54/100,000 by 2030. The company will actively promote market rollout pending final approval.